Pharmacogenetic Risk Stratification in Angiotensin-Converting Enzyme Inhibitor-Treated Patients with Congestive Heart Failure: A Retrospective Cohort Study

BACKGROUND: Evidence for pharmacogenetic risk stratification of angiotensin-converting enzyme inhibitor (ACEI) treatment is limited. Therefore, in a cohort of ACEI-treated patients with congestive heart failure (CHF), we investigated the predictive value of two pharmacogenetic scores that previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelveg-Kristensen, Karl Emil, Busk Madsen, Majbritt, Torp-Pedersen, Christian, Køber, Lars, Egfjord, Martin, Berg Rasmussen, Henrik, Riis Hansen, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669156/
https://www.ncbi.nlm.nih.gov/pubmed/26633885
http://dx.doi.org/10.1371/journal.pone.0144195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669156/
https://www.ncbi.nlm.nih.gov/pubmed/26633885
http://dx.doi.org/10.1371/journal.pone.0144195

Ejemplares similares